GLP-1 drugs show promise for addiction, but evidence remains incomplete

A Journal of Clinical Investigation Viewpoint highlights growing evidence that GLP-1 receptor agonists, particularly semaglutide, may reduce alcohol consumption and some other substance-related outcomes by acting on brain systems involved in reward, motivation, stress, and emotion. However, the authors caution that efficacy for substance use disorders is not yet firmly established and call for further research into optimal dosing, treatment duration, patient selection, mechanisms, and effects across different addictions. Recent randomized trials have shown encouraging results for semaglutide in reducing alcohol consumption, though an earlier exenatide trial did not improve primary drinking outcomes. Evidence for tobacco use disorder is variable, while a small liraglutide pilot trial reported reduced opioid craving. The drugs, already established for diabetes and obesity, may also address comorbid health issues common in addiction patients. The authors note that enthusiasm has sometimes outpaced evidence, and many questions remain about treatment duration and patient response variability. Most studies have focused on alcohol, opioid, and tobacco use disorders, leaving stimulant, cannabis, and gambling disorders unexplored. Ongoing trials could confirm whether these therapies become a transformative addiction treatment option.